POM-V Prescription Required Companion Animal

Banacep Vet 5 mg Film-coated Tablet for Dogs and Cats Benazepril Hydrochloride

Active ingredient: Benazepril Hydrochloride

Form

Tablet

Species

Cats Dogs

Manufacturer

Laboratorios Calier, S.A.

VMD MA No.

20634/5006

What it's used for

Dogs: Treatment of congestive heart failure. Cats: Reduction of proteinuria associated with chronic kidney disease.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Benazepril Hydrochloride

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Banacep Vet 5 mg Film-coated Tablet for Dogs and Cats Benazepril Hydrochloride — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 18 Mar 2026.

Dogs:
Treatment of congestive heart failure.
Cats:
Reduction of proteinuria associated with chronic kidney disease.

Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal
failure.

Revised: June 2024
AN: 01837/2023
S)
Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.
Do not use during pregnancy or lactation (see section 4.7).

Dogs:
Undetermined frequency
(cannot be estimated from the
available data):
Vomiting
Incoordination
Fatigue
Elevated creatinine*
*In dogs with chronic kidney disease, at the start of therapy. A moderate increase in
plasma creatinine concentrations following administration of ACE inhibitors is

Revised: June 2024
AN: 01837/2023
S)
compatible with the reduction in glomerular hypertension induced by these agents
and is therefore not necessarily a reason to stop therapy in the absence of other
signs.
In double-blind clinical trials in dogs with congestive heart failure, the veterinary
medicinal product was well tolerated with an incidence of adverse reactions lower
than observed in placebo-treated dogs.
Cats:
Rare
(1 to 10 animals / 10,000
animals treated):
Diarrhoea, Emesis
Anorexia, Dehydration, Lethargy
Undetermined frequency
(cannot be estimated from the
available data):
Elevated creatinine*
Increased appetite, Weight gain
*In cats with chronic kidney disease, at the start of therapy. A moderate increase in
plasma creatinine concentrations following administration of ACE inhibitors is
compatible with the reduction in glomerular hypertension induced by these agents
and is therefore not necessarily a reason to stop therapy in the absence of other
signs.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder <or its local representative> or the national
competent authority via the national reporting system. See the package leaflet for
contact details.

None.

Special precautions for use in animals
No evidence of renal toxicity of the veterinary medicinal product has been observed
in dogs or cats during clinical trials however, as is routine in cases of chronic kidney
disease, it is recommended to monitor plasma creatinine, urea and erythrocyte
counts during therapy.
The efficacy and safety and the efficacy of veterinary medicinal product has not been
established in dogs and cats below 2.5 kg body weight.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Wash hands after use.
In case of accidental oral ingestion, seek medical advice immediately and show the
label or the package leaflet to the physician.
Pregnant women should take special care to avoid accidental oral exposure,
because angiotensin converting enzyme (ACE) inhibitors have been found to affect
the unborn child during pregnancy in humans.
Special precautions for the protection of the environment
Not applicable.
Other precautions:
Not applicable.

In dogs with congestive heart failure, the veterinary medicinal product has been given
in combination with digoxin, diuretics, pimobendan and anti-arrhythmic veterinary
medicinal products without demonstrable adverse interactions.

Revised: June 2024
AN: 01837/2023
S)
In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflamatory
Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal
function. The combination of the veterinary medicinal product and other anti-
hypertensive agents (e.g. calcium channel blockers, -blockers or diuretics),
anaesthetics or sedatives may lead to additive hypotensive effects. Therefore,
concurrent use of NSAIDs or other medications with a hypotensive effect should be
considered with care. Renal function and signs of hypotension (lethargy, weakness
etc) should be monitored closely and treated as necessary.
Interactions with potassium preserving diuretics like spironolactone, triamterene or
amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels
when using the veterinary medicinal product in combination with a potassium sparing
diuretic because of the risk of hyperkalaemia.

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.